GlaxoSmithKline has been boosted by the news that it has received nine additional government orders for the company's investigational swine flu vaccine.

Announcing its financial results for the second quarter at the end of July, GSK also confirmed that it had contracts in place to supply 195 million doses of its H1N1 adjuvanted influenza vaccine and had a variety of agreements in place with the US Government to supply pandemic products worth $250 million. Since then, nine government contracts have been signed for 96 million doses.

GSK, which noted that discussions continue with governments for further supplies, said that supplies of the vaccine will be available from September onwards. The company added that it has allocated 20% of production at its Canadian manufacturing site to developing countries, including a proposed donation of 50 million doses of the H1N1 vaccine to the World Health Organisation.

GSK said it is operating a tiered-pricing policy for the vaccine, based on World Bank classification of countries and eligibility through the Global Alliance for Vaccines and Immunisation. Elsewhere the vaccine could generate billions of dollars for the company.

A number of other companies are preparing their H1N1 treatments and Novartis has revealed it has started human testing of its swine flu vaccine candidates in a number of countries, including the USA, the UK and Germany. Sanofi-Aventis says it will start trials in the next few days, while AstraZeneca’s MedImmune unit will begin clinical trials in the USA in about two weeks.